BG Medicine Revenues Jump to $622K in Q2; Firm Withdraws CardioScore 510(k) | GenomeWeb

BG Medicine said this week that revenues for the second quarter increased 181 percent year over year, rising to $622,000 from $221,000 a year ago and beating the average Wall Street estimate of $520,000.

Product revenues spiked to $566,000 from $46,000 a year ago, "reflecting increasing demand for the BGM Galectin-3 test," the company said, while service revenues dropped to $56,000 from $175,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.